Journal of Leukocyte Biology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published online as doi:10.1189/jlb.0305153 on June 10, 2005

Published online before print June 10, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0305153v1
78/3/762    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karlsson, J.
Right arrow Articles by Movitz, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karlsson, J.
Right arrow Articles by Movitz, C.
(Journal of Leukocyte Biology. 2005;78:762-771.)
© 2005 by Society for Leukocyte Biology

Neutrophil NADPH-oxidase activation by an annexin AI peptide is transduced by the formyl peptide receptor (FPR), whereas an inhibitory signal is generated independently of the FPR family receptors

Jennie Karlsson*, Huamei Fu*, François Boulay{dagger}, Claes Dahlgren*, Kristoffer Hellstrand{ddagger} and Charlotta Movitz{ddagger},1

* Department of Rheumatology and Inflammation Research, Göteborg University, Göteborg, Sweden;
{dagger} DRDC/BBSI (UMR 5092, CEA/CNRS/UJF), Grenoble, France; and
{ddagger} Department of Clinical Virology, Göteborg University, Göteborg, Sweden

1Correspondence: Department of Clinical Virology, Göteborg University, Guldhedsgatan 10, S-413 46 Göteborg, Sweden. E-mail: charlotta.movitz{at}microbio.gu.se


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Truncation of the N-terminal part of the calcium-regulated and phospholipid-binding protein annexin AI has been shown to change the functional properties of the protein and to generate immunoregulatory peptides. Proinflammatory as well as anti-inflammatory signals are triggered by these peptides, and the two formyl peptide receptor (FPR) family members expressed in neutrophils, FPR and FPR-like 1 (FPRL1), have been suggested to transduce these signals. We now report that an annexin AI peptide (Ac9–25) activates, as well as inhibits, the neutrophil release of superoxide anions. Results obtained from experiments with receptor antagonists/inhibitors, desensitized cells, and transfected cells reveal that the Ac9–25 peptide activates the neutrophil reduced nicotinamide adenine dinucleotide phosphate oxidase through FPR but not through FPRL1. The Ac9–25 peptide also inhibits the oxidase activity in neutrophils triggered, not only by the FPR-specific agonist N-formyl-Met-Leu-Phe but also by several other agonists operating through different G protein-coupled receptors. Our data show that the two signals generated by the Ac9–25 peptide are transmitted through different receptors, the inhibitory signal being transduced by a not-yet identified receptor distinct from FPR and FPRL1.

Key Words: granulocytes • inflammation • resolution • cell activation • signal transduction


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Accumulation and activation of neutrophil granulocytes at inflammatory sites are of profound importance in our innate immune response to infection. The elimination of invading microbes relies on a proper activation of the superoxide generating reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase present in these cells. However, an extensive or prolonged release of reactive oxygen species may impair the function of other immune reactive cells and induce damage to surrounding tissues [1 2 3 4 ]. The importance of mediators that regulate neutrophil function and thereby, the inflammatory process is obvious, and a wide range of anti-inflammatory mediators has been described, which in one way or another, suppress neutrophil function and promote resolution of the innate immune reaction (reviewed in ref. [5 ]). Annexin AI is one such mediator suggested to participate in the signaling network that regulates inflammation [6 7 8 9 ]. This protein belongs to a large family of calcium-regulated and phospholipid-binding proteins (reviewed in ref. [10 ]). The cleavage of annexin AI in the N-terminal domain affects the membrane-binding properties of the truncated protein [11 ] but also generates peptides of importance for resolution of the inflammatory process (reviewed in ref. [5 ]).

Recent findings suggest that annexin AI-derived peptides possess not only anti-inflammatory activities but also can activate neutrophils directly. The triggering of neutrophil function as well as the anti-inflammatory signaling have been suggested to rely on the interactions with one or possibly both neutrophil members of the formyl peptide receptor (FPR) family [8 , 12 ]. The two FPR family members expressed in neutrophils, FPR and FPR-like 1 (FPRL1), belong to the G protein-coupled seven transmembrane receptor family. FPRL1 was originally cloned from human phagocytes by low-stringency hybridization of a cDNA library with the FPR sequence and initially defined as an orphan receptor [13 ]. The first ligand shown to bind this receptor with high affinity was the lipid mediator lipoxin A4 (LXA4) [14 ]. During the past few years, several other ligands for FPRL1 have been identified [15 16 17 18 ]. It should be noted that despite the fact that different protein/peptide ligands bind to the same receptor, they do not contain any sequence homologies. Also, whereas the protein/peptide ligands have in common that they are potent activators of neutrophils [15 , 16 , 18 ], LXA4 is an inhibitor of neutrophil functions such as adhesion and chemotaxis [19 , 20 ]. The fact that the cytoplasmic regions of FPRL1 share approximately 80% identity with FPR suggests that signaling from the two receptors should be similar, but so far, all agonists described to interact with FPR trigger neutrophil activation. Recently published experiments using a desensitization protocol and receptor expressing human embryonic kidney (HEK)293 cells reveal that N-terminal annexin AI peptides activate cells through FPR and FPRL1 (and also through FPRL2, which is expressed in monocytes) [12 ]. Moreover, the inhibitory effect of such peptides has been shown to be mediated, at least in part, by FPR [8 , 21 ], although a recent study in mice suggests that the deactivating signal is independent of FPR but might involve FPRL1 [22 ]. Taken together, these data suggest that the receptor system in neutrophils responsible for the activating and deactivating actions of the annexin AI-derived peptides needs to be characterized in more detail.

In this study, we show that a peptide, derived from the N-terminal region of annexin AI, activates neutrophils to produce and release superoxide anions. The signals activating the NADPH-oxidase were generated by FPR. We also show that the inhibitory signal generated in neutrophils by the same peptide was transduced by a not-yet identified receptor distinct from FPR and FPRL1 and affects the NADPH-oxidase activity induced by several different chemoattractants.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Peptides and reagents
Dextran and Ficoll-Paque were from Pharmacia (Uppsala, Sweden). The N-terminal annexin AI peptide (Ac9–25), with the amino acid sequence acetyl-QAWFIENEEQEYVQTVK, was synthesized and high-pressure liquid chromatography (HPLC)-purified by Ross-Petersen ApS (Holte, Denmark). The peptide was dissolved in alkaline phosphate-buffered saline and stored at –70°C. The hexapeptides Trp-Lys-Tyr-Met-Val-Met-NH2 (WKYMVM) and Trp-Lys-Tyr-Met-Val-D-Met-NH2 (WKYMVm) were synthesized and HPLC-purified by Alta Bioscience (University of Birmingham, UK). The formylated peptide N-formyl-Met-Leu-Phe (fMLF), phorbol myristate acetate (PMA), as well as N-t-butoxycarbonyl (boc)-MLF were from Sigma Chemical Co. (St. Louis, MO). These substances were dissolved in dimethyl sulfoxide (DMSO) to 10–2 M and stored at –70°C until used. The FPRL1 antagonist WRWWWW [23 ] was purchased from Genscript Corp. (Scotch Plains, NJ) and dissolved in DMSO to 10–2 M and stored at –70°C. Cyclosporin H was kindly provided by Novartis Pharma (Basel, Switzerland) and diluted in DMSO to 10–3 M and stored at –70°C. Interleukin-8 (IL-8) was from R&D Systems (Minneapolis, MN) and dissolved in Krebs-Ringer glucose (KRG) buffer containing 0.5% (w/v) bovine serum albumin and stored at –70°C. Horseradish peroxidase (HRP) was from Boehringer-Mannheim (Mannheim, Germany). Isoluminol was purchased from Sigma Chemical Co. The gelsolin peptide QRLFQVKGRR (residues 160–169; PBP10) was prepared by solid-phase peptide synthesis and coupled to rhodamine [24 ] and was a generous gift from Dr. Paul Janmey (University of Pennsylvania, Philadelphia). All peptides/proteins/antagonists were further diluted in KRG.

Isolation of human neutrophils
Neutrophil granulocytes were isolated from buffy coats obtained from healthy adults. After dextran sedimentation at 1 g, hypotonic lysis of the remaining erythrocytes, and centrifugation in a Ficoll-Paque gradient [25 ], the neutrophils were washed twice and resuspended (1x107 cells/ml) in KRG phosphate buffer, containing glucose (10 mM), Ca2+ (1 mM), and Mg2+ (1.5 mM; pH 7.3). The cells were stored on melting ice until used.

Stable expression of FPRs in undifferentiated HL-60 cells
The stable expression of FPR, FPRL1, and FPRL2 in undifferentiated HL-60 cells has been described previously [16 , 18 ]. The control experiments with the specific agonists (fMLF for FPR and WKYMVM/m for FPRL1 and FPRL2) were performed at each experimental event and turned out positive. Cells were cultured in RPMI-1640 medium/glutaMax I, and the maximal density was maintained below 2 x 106 cells/ml.

Differentiation of non-transfected HL-60 cells
HL-60 cells were passed once a week in RPMI medium supplemented with 10% (v/v) heat-inactivated fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine. The cells were induced to differentiate by the addition of DMSO to a final concentration of 1% (v/v). The cells were harvested after 5 days of cultivation, washed, and resuspended in KRG. If the cells were cultivated in the presence of fMLF and WKYMVm, 10–7 M fMLF and 10–7 M WKYMVm were added 1, 2, and 5 days after addition of DMSO.

Neutrophil NADPH-oxidase activity
Neutrophil production and release of superoxide anions were measured by an isoluminol-enhanced chemiluminescence (ECL) assay [26 ]. The ECL activity was measured in a six-channel Biolumat LB 9505 apparatus (Berthold Co., Wildbad, Germany), using disposable, 4 ml polypropylene tubes with a 400-µl reaction mixture containing 4 x 105 neutrophils, HRP (4 U), and isoluminol (20 µM). boc-MFL (40 µl, 10–5 M), cyclosporin H (10–6 M), PBP10 (1 µM), or WRWWWW (5x10–6 M) was added as indicated in Results. The measuring tubes were equilibrated for 5 min at 37°C, and the cells were activated by addition of one or two peptide/protein agonists at different time-points. The light emission was recorded continuously.

Determination of changes in cytosolic calcium
Cells were loaded with 2 µM Fura-2/AM (Molecular Probes, Eugene, OR), according to the instructions given by the manufacturer. Calcium measurements were carried out as described earlier [16 ] using an LC50 fluorescence spectrophotometer (LS50B, Perkin Elmer, Wellesley, MA). Intracellular calcium concentrations ([Ca2+]i) were calculated using the formula: [Ca2+]i = Kd(F–Fmin)/(Fmax–;F) with a dissociation constant (Kd) for Fura-2 of 224 nM, where Fmax is the fluorescence in the presence of 0.04% Triton X-100, and Fmin is the fluorescence after the addition of 5 mM EGTA and 30 mM Tris-HCl, pH 8.7.

Statistical analysis
Two-tailed, paired Student’s t-test was performed to determine statistical significance. A Pvalue of <0.05 was regarded as significant.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
The annexin AI peptide activates the neutrophil NADPH-oxidase through FPR
A synthetic peptide identical with an annexin AI sequence spanning from amino acid 9 through 25 (Ac9–25), close to the N terminus of the protein, was used to activate neutrophils. The secretion of superoxide anions following activation of the neutrophil NADPH-oxidase was used as a read-out system. A respiratory burst was triggered by Ac9–25, and the time course of the response was similar to that induced by several agonists operating through one or the other of the neutrophil chemoattractant receptors. The onset of superoxide release was rapid and reached a peak value after 1–2 min, and the response then declined rapidly (Fig. 1 ). The NADPH-oxidase activity induced by Ac9–25 was concentration-dependent with a 50% effective concentration value of approximately 20 µM and reached its maximum value at approximately 50 µM. The activity induced by Ac9–25 was lower than that induced by the well-characterized, formylated peptide fMLF, reaching a maximum rate of production corresponding to approximately one-tenth of that induced by a saturating concentration of fMLF. Activated neutrophils sometimes assemble the NADPH-oxidase intracellularly [27 ]. No such assembly was obtained using Ac9–25 as the trigger (data not shown), suggesting that the activity induced by the peptide originated exclusively from oxidase activity in the plasma membrane, and as a consequence, the reactive oxygen species were secreted. This is an activation pattern, which Ac9–25 shares with all chemoattractants, earlier shown to activate the neutrophil NADPH oxidase [28 , 29 ].



View larger version (17K):
[in this window]
[in a new window]
  		Figure 1. Ac9–25 induced release of superoxide anions. Neutrophils were activated by addition of increasing concentrations of Ac9–25 (10–100 µM final concentration). The release of superoxide anions was measured by isoluminol-ECL. Abscissa, Time of study; ordinate, superoxide production, given as 106 counts per minute (Mcpm). The curves are from a representative experiment.

 
Annexin AI-derived peptides have been shown to activate neutrophils through binding to the FPR and its closely related member of the same receptor family, FPRL1. To determine the importance of these receptors during activation of the NADPH- oxidase, we studied the effects of the FPR-specific receptor antagonists boc-MLF and cyclosporin H [18 ]. The specificity of the antagonists is illustrated by the fact that they both totally block the NADPH-oxidase activity evoked by fMLF but are without effect on the oxidase activity induced by the FPRL1-binding hexapeptide WKYMVM (Fig. 2A , insets). Neutrophils were preincubated with an antagonist before addition of Ac9–25. The oxidase activity induced by Ac9–25 was totally inhibited by boc-MLF (Fig. 2A , upper panel) as well as by cyclosporin H (Fig. 2A , lower panel), suggesting that Ac9–25 operates as a ligand for FPR and activates the NADPH-oxidase through this receptor. The recently described FPRL1 antagonist, WRWWWW, was also used to inhibit the Ac9–25-induced activity. The characteristic of the WRWWWW peptide is that it antagonized the burst induced by the FPRL1 ligand WKYMVM, whereas it is without effect on fMLF (Fig. 2B , inset) as well as on Ac9–25 (Fig. 2B) . From these results, we conclude that FPRL1 is not involved in the activation process. The importance that FPR but not FPRL1 during Ac9–25 induces activation was verified using a selective desensitization protocol (Fig. 3 ). Neutrophils were activated with fMLF (Fig. 3 , upper panel) and WKYMVM (Fig. 3 , lower panel), respectively. The cells were then challenged with Ac9–25. The Ac9–25 peptide induced a second burst of superoxide in WKYMVM/FPRL1-desensitized neutrophils but not in those cells desensitized to fMLF/FPR. From the results presented, using the receptor-specific antagonist and the receptor-specific desensitization protocols, we suggest that Ac9–25 acts as an activating mediator through FPR but not FPRL1.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 2. Inhibition of Ac9–25 induced release of superoxide anions by receptor antagonists. (A) Neutrophils were incubated with (solid line) or without (broken line) 10–5 M boc-MLF (upper panel) or 10–6 M cyclosporin H (lower panel) for 5 min at 37°C and activated by the addition of Ac9–25 (50 µM final concentration). The release of superoxide anions was measured by isoluminol-ECL. Abscissa, Time of study; ordinate, superoxide production given as Mcpm. The curves are from a representative experiment. The effects of boc-MLF (upper inset) and cyclosporin H (lower inset) on fMLF- and WKYMVM (10–7 M final concentration)-induced radical production are expressed as percent of control cells (cells incubated in the absence of antagonist) and shown as mean ± SEM, n = 3. (B) Neutrophils were incubated with 5 x 10–6 M (broken line) or without WRWWWW (solid line) for 5 min at 37°C and activated by addition of Ac9–25 (50 µM final concentration). The release of superoxide anions was measured by isoluminol-ECL. Abscissa, Time of study; ordinate, superoxide production given as Mcpm. The curves are from representative experiments. The effects of the FPRL1 antagonist WRWWWW on WKYMVM and fMLF (10–7 M final concentration, inset)-induced superoxide anion release are included as control (data are presented as percent of control cells and shown as mean±SEM, n=3).

 


View larger version (16K):
[in this window]
[in a new window]
  		Figure 3. Desensitization of Ac9–25 induced NADPH-oxiadse activity by fMLF. Neutrophils triggered with fMLF (10–7 M, solid line, upper panel) or WKYMVM (10–7 M, solid line, lower panel) or simply preincubated without agonist (broken lines) were activated through addition of Ac9–25 (50 µM final concentration). The release of superoxide anions was measured by isoluminol-ECL. Abscissa, Time of study; ordinate, superoxide production given as Mcpm. The curves are from representative experiments.

 
Calcium mobilization in FPR- and FPRL1/2-expressing HL-60 cells by Ac9–25
To confirm our data, we determined the activation pattern by the Ac9–25 peptide in stable transfectants of HL-60 cells expressing the different members of the FPR family. The results obtained in the calcium mobilization assay suggest that Ac9–25 is a FPR agonist. The [Ca2+]i of HL-60-FPRL1 also remained at a resting level when Ac9–25 was added (Fig. 4 , lower-left inset), whereas it was increased in HL-60-FPR (Fig. 4 , upper panel). No transient increase in [Ca2+]i was obtained with the peptide in HL-60-FPRL2 (Fig. 4 , lower-right inset). Although not normally expressed in neutrophils, this receptor is 83% identical to FPRL1. To summarize, these data strongly imply that the annexin mimetic Ac9–25 activates neutrophils through FPR and not through FPRL1.



View larger version (17K):
[in this window]
[in a new window]
  		Figure 4. Ac9–25 induced calcium mobilization in FPR-, FPRL1-, and FPRL2-transfected HL-60 cells. Changes in intracellular calcium were measured in undifferentiated HL-60 cells stably transfected with FPR (upper panel), FPRL1 (lower-left inset), or FPRL2 (lower-right inset). Cells loaded with Fura-2 were activated through an addition of Ac9–25 (100 µM final concentration), and the change in fluorescence was measured. Abscissa, Time of study; ordinate, intracellular Ca2+ concentration in nM. The curves are from representative experiments.

 
Priming and desensitization/inhibition of fMLF induced oxidase activity
The cross-desenitizing potency of two agonists is dependent on the concentration as well as on the affinity for the receptors. The desensitizing/inhibitory effect induced by Ac9–25 on respiratory burst activity could thus differ from that described earlier for fMLF. In accordance with this, we found, when using the desensitization protocol described above but with the FPR agonists Ac9–25 and fMLF added in reverse order, an inhibition of approximately 50% when Ac9–25 was added first followed by fMLF (Fig. 5A ). The inhibition was increased to ~80% by raising the Ac9–25 concentration to 100 µM (Fig. 5B) . The lower concentration of Ac9–25 (i.e., 20 µM) only had an inhibitory effect if the fMLF concentration was decreased to 10–8 M.



View larger version (26K):
[in this window]
[in a new window]
  		Figure 5. Ac9–25 inhibits the fMLF-induced release of superoxide anions. (A) Neutrophils were incubated with (broken line) or without (solid line) Ac9–25 (50 µM final concentration) and reactivated through addition of fMLF (10–7 M final concentration). The release of superoxide anions was measured by isoluminol-ECL. The time is given on the abscissa, and the amount of superoxide on the ordinate is given as Mcpm. The curves are from a representative experiment. (B) Neutrophils were incubated with different concentrations of Ac9–25 (0–100 µM final concentration) for 5 min at 37°C and then activated through addition of fMLF (10–7 or 10–8 M final concentration). The release of superoxide anions was determined from the peak values of the responses and expressed as percent of control (i.e., the response from cells incubated in the absence of Ac9–25) and given as mean ± SEM, n = 3. **, P < 0.01, versus cells incubated in the absence of Ac9–25. (C) Neutrophils were incubated with (broken line) or without (solid line) a suboptimal concentration of fMLF (10–8 M final concentration) and activated through addition of a new dose of fMLF (10–7 M final concentration). The release of superoxide anions was measured by isoluminol-ECL. The time is given on the abscissa, and the amount of superoxide on the ordinate is given as Mcpm. The curves are from a representative experiment. The release of superoxide anions is also presented as the response expressed as percent of control cells (i.e., the response from cells incubated in the absence of 10–8 M fMLF before stimulation with 10–7 M fMLF) and is given as mean ± SEM, n = 4. *, P< 0.05.

 
Proper desensitization with the fMLF/FPR receptor-agonist pair is obtained only when the cells are stimulated and restimulated with the same concentration of the agonist. If, however, the concentration of an agonist in the first step of activation is suboptimal, the neutrophils will become primed rather than desensitized in their response to the higher concentration of the agonist and increase their respiratory burst (Fig. 5C) . Priming is achieved through an induction of secretion, leading to an exposure of new receptors stored in easily mobilizable vesicles and granules [30 , 31 ]. The level of burst induced by Ac9–25 corresponds with that induced by a suboptimal concentration of fMLF. Despite this similarity, the neutrophil response to a high concentration of fMLF was not primed when the cells were first challenged with the Ac9–25 peptide (Fig. 5A) . These data suggest that Ac9–25 inhibits the fMLF-induced response by a mechanism distinct from what is known as homologous receptor desensitization. It should also be noticed that Ac9–25 totally desensitizes/inhibits a second stimulation of Ac9–25 (50 µM peptide used at each stimulation; data not shown). At the present time, it is unknown if this is a result of homologous desenstitization and/or an inhibitory signal induced by the peptide.

Ac9–25 inhibits superoxide anion production in neutrophils through a receptor distinct from FPR and FPRL1
The fact that Ac9–25 is unable to prime the fMLF-triggered activity suggests that the peptide, in addition to its activating property, also evokes an inhibitory signal that may affect the oxidase activity induced by other stimuli. We used several different approaches to determine if Ac9–25 inhibits neutrophil respiratory burst through the receptor responsible for activation, i.e., FPR. The receptor-specific antagonist boc-MLF was used to block signaling through FPR. Neutrophils were incubated with boc-MLF, treated with Ac9–25, and challenged with the FPRL1-specific agonist WKYMVM. In accordance with earlier presented data, the Ac9–25-induced respiratory burst is antagonized by the FPR antagonist (Figs. 2A and 6A ) but has no effect on WKYMVM (Fig. 2A , upper panel inset). The inhibitory effect that Ac9–25 possesses on the WKYMVM-triggered activity also remains in the presence of boc-MLF (Fig. 6A) . To investigate this phenomenon in more detail, the effects of Ac9–25 on the response induced by other agonists operating through G protein-coupled receptors were investigated. The peptide WKYMVm, C5a, IL-8, and PAF evoke a respiratory burst. The NADPH-oxidase activity induced by these agonists was inhibited by Ac9–25 in the presence of boc-MLF (Fig. 6B) . When using a stimulus such as PMA, which bypasses cell-surface receptors and directly activates protein kinase C (PKC), Ac9–25 was without effect on the respiratory burst (Fig. 6C) . This shows that the inhibitory effect induced by Ac9–25 is not related to an effect directly on the oxidase and second, that there is no effect on signaling downstream of PKC. These results suggest that the inhibitory signal induced by Ac9–25 is generated through a receptor distinct from FPR. This suggestion gained further support by the results obtained with differentiated HL-60 cells. When these cells were differentiated in the presence of fMLF and WKYMVm (an agonist to FPRL1 and FPR), they were unable to elicit any burst activity when stimulated with the FPR-specific ligand fMLF, the FPRL1-specific ligand WKYMVM, or Ac9–25 (Fig. 7 , lower panels a–c, respectively). To study the importance of FPR and FPRL1 during Ac9–25-induced inhibitory signaling, these cells were stimulated with Ac9–25 before stimulation with C5a, which binds to the G protein-coupled C5aR. The burst induced by C5a was, however, reduced when the cells were preincubated with Ac9–25 (Fig. 7 , upper panel). This suggests that the inhibitory signal is also generated in cells lacking functional FPRs and FPRL1s. By using HL-60 cells, differentiated only in the presence of fMLF, we could also confirm our data presented in this study, showing that Ac9–25 activates neutrophils through FPR (data not shown).



View larger version (23K):
[in this window]
[in a new window]
  		Figure 6. Ac9–25 induced inhibition of neutrophil NADPH-oxidase activity in the presence of an FPR antagonist. (A) Neutrophils incubated with (broken line) or without (dotted line) boc-MLF (10–5 M final concentration) were activated through the addition of Ac9–25 (50 µM final concentration). The cells were then challenged with the FPRL1 agonist WKYMVM (10–7 M final concentration). The control (solid line) was preincubated in the absence of boc-MLF and Ac9–25 and challenged only with WKYMVM. The release of superoxide anions was measured by isoluminol-ECL. The time is given on the abscissa, and the amount of superoxide is on the ordinate given as Mcpm. The curves are from representative experiments. (B) Neutrophils were incubated with boc-MLF (10–5 M final concentration) for 5 min at 37°C and stimulated with Ac9–25 (50 µM final concentration). The cells were reactivated through addition of one of five different chemoattractants [10–7 M WKYMVM, 10–8 M WKYMVm, 0.5 µg/ml IL-8, 5x10–7 M platelet-activating factor (PAF), or 0.1 µg/ml C5a, given as final concentrations]. The release of superoxide anions was determined from the peak values of the responses and expressed as percent of control (i.e., the response from cells incubated in the absence of Ac9–25) and is given as mean ± SD (n=3–4). *, P < 0.05; **, P < 0.01, versus cells incubated in the absence of Ac9–25. (C) Neutrophils were activated by addition of Ac9–25 (50 µM final concentration, broken line) and then reactivated by PMA (5x10–8 M final concentration). The nonpretreated control cells (solid line) were activated with PMA in parallel with the Ac9–25-treated cells. The release of superoxide anions was measured by isoluminol-ECL. The time is given on the abscissa, and the amount of superoxide on the ordinate is given as Mcpm. The curves are from a representative experiment.

 


View larger version (17K):
[in this window]
[in a new window]
  		Figure 7. Ac9–25 inhibits C5a-induced superoxide anion release in FPR/FPRL1-desensitized HL-60 cells, which were differentiated in the presence of fMLF (10–7 M final concentration) and WKYMVm (10–7 M final concentration) for 5 days. These cells were unresponsive with respect to superoxide release when triggered by the agonists fMLF (lower panel a), WKYMVM (lower panel b), or Ac9–25 (lower panel c). Cells, differentiated in the presence of fMLF/WKYMVm, released superoxide anions when triggered by C5a (upper panel, solid line), whereas cells preincubated with Ac9–25 (50 µM final concentration) before C5a stimulation responded with a reduced superoxide anion release (dotted line). The release of superoxide anions was measured by isoluminol-ECL. The time is given on the abscissa, and the amount of superoxide is on the ordinate given as Mcpm. The curves are from representative experiments.

 
To elucidate the role for FPRL1 in Ac9–25-mediated inhibition, the newly described FPRL1 antagonist WRWWWW was used. This peptide antagonizes WKYMVM but not fMLF-induced NADPH-oxidase activity (Fig. 2B) . The fMLF-induced response was inhibited/reduced by Ac9–25, also when FPRL1 was blocked by the receptor-specific antagonist (Fig. 8 ). It is thus obvious that Ac9–25 mediates its inhibitory signal through a receptor distinct from FPRL1. Another approach to determine the role of FPRL1 is to use PBP10. This is a phosphatidylinositol 4,5-bisphosphate (PIP2)-binding peptide derived from the cytoskeleton protein gelsolin. We have recently shown that this peptide inhibits signaling from FPRL1 but not from FPR [24 ]. The respiratory burst induced by WKYMVM is totally inhibited by PBP10 (Fig. 9 , lower left panel), whereas the burst induced by fMLF is unaffected (Fig. 9 , lower right panel). Ac9–25 inhibited the fMLF-induced response also when FPRL1 signaling was blocked by PBP10 (Fig. 9 , upper panel) as compared with fMLF-stimulated cells incubated in the absence of annexin AI peptide (Fig. 9 , lower right panel).



View larger version (20K):
[in this window]
[in a new window]
  		Figure 8. The FPRL1 antagonist WRWWWW is without effect on Ac9–25-mediated inhibition of superoxide release. Neutrophils incubated with (solid line) or without (dotted line) the FPRL1 antagonist WRWWWW (5x10–6 M final concentration) were activated through an addition of Ac9–25 (50 µM final concentration). The cells were then challenged with the FPR agonist fMLF (10–7 M final concentration). The control cells (broken line) were preincubated in the absence of WRWWWW and Ac9–25 and challenged only with fMLF. The release of superoxide anions was measured by isoluminol-ECL. The time is given on the abscissa, and the amount of superoxide is on the ordinate given as Mcpm. The curves are from a representative experiment.

 


View larger version (18K):
[in this window]
[in a new window]
  		Figure 9. The PIP2-binding peptide PBP10 is without effect on Ac9–25-mediated inhibition of superoxide release. Neutrophils were preincubated with (dotted line) or without (solid line) PBP10 (1 µM final concentration) for 5 min at 37°C and activated with Ac9–25 (50 µM final concentration) followed by fMLF (10–7 M final concentration). The amount of superoxide anion release, in the absence of Ac9–25, and the effects of PBP10 are shown for the FPRL1 agonist WKYMVM (lower left panel) and for the FPR agonist fMLF (lower right panel). The release of superoxide anions was measured by isoluminol-ECL. The time is given on the abscissa, and the amount of superoxide is on the ordinate given as Mcpm. The curves are from representative experiments.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Human neutrophils express two members of the FPR family (FPR and FPRL1), which possess a high degree of amino acid identity, particularly in the signaling cytoplasmic domains. The signals generated by these receptors have been described to activate the functional repertoire (chemotaxis, secretion, respiratory burst) of the cells or inhibit the same repertoire, depending on the particular triggering agonist [18 19 20 , 32 ]. It has even been suggested that the duality in signaling, that is, generation of inhibitory signals and activating signals, respectively, can be triggered, not only by different agonists binding to the same receptor but also by a single agonist binding to its receptor [8 ]. Peptides derived from the N terminus of the calcium-regulated and phospholipid-binding protein annexin AI possess this type of functional duality. These peptides have not only been suggested to induce neutrophil chemotactic activity through triggering of FPR and FPRL1 but also to initiate inhibitory signals, supposedly through binding to one or the other of these receptors [8 , 12 , 22 ]. In this study, we show that an annexin AI peptide, Ac9–25, activates the neutrophil NADPH oxidase through FPR but not through FPRL1. We also present data showing that the Ac9–25 peptide triggers a not-yet identified inhibitory signal, which is achieved through interaction with a receptor distinct from FPR and FPRL1.

We used receptor-specific agonists and antagonists to identify the receptors involved in Ac9–25 signaling. The formylated peptide fMLF, a classical high-affinity ligand for the chemoattractant receptor FPR, was used together with the antagonists boc-MLF and cyclosporin H (reviewed in ref. [33 ]). FPRL1, originally defined as an orphan receptor, is a promiscuous receptor to which the peptide WKYMVM is one of the more potent high-affinity and specific ligands [16 ]. Recently, the peptide WRWWWW was shown to be a FPRL1-specific antagonist [23 ]. This antagonist inhibits several different FPRL1 agonists and even agonists that do not share identical binding domains in FPRL1 [23 , 34 ]. This peptide was used, together with WKYMVM, to evaluate the role of FPRL1 in neutrophil triggering by Ac9–25. Receptor desensitization experiments using agonists specific for FPR and FPRL1, respectively, strongly suggest that the signal for activation of the neutrophil NADPH-oxidase by Ac9–25 originates from FPR and not from FPRL1. This conclusion was further supported from experiments with the receptor-specific antagonists cyclosporin H and boc-MLF. These antagonists totally block the Ac9–25-induced respiratory burst, whereas WRWWWW was without any effect. Our results were finally confirmed using FPR-, FPRL1-, and FPRL2-expressing, undifferentiated HL-60 cells. Calcium mobilization experiments reveal that Ac9–25 triggers a response in FPR-expressing cells but not in those expressing FPRL1 or FPRL2. These results are not in agreement with earlier data presented using stably transfected HEK293 cells [8 ]. At the present time, we don’t know the reason for this, but the important finding is that our peptide retains the inhibitory effect but lacks the ability to activate through FPRL1.

A large number of ligands have been identified for FPRL1, including a number of peptides with microbial origin as well as the endogenous acute-phase reactant serum amyloid A [17 ] and the cathelicidin LL-37 [35 ]. For FPR, conversely, only a few ligands, in addition to the formylated peptides, have been identified [8 , 36 ]. It may, however, be that FPR is also promiscuous with respect to ligand binding, and more proteins/peptides will be added in the future.

The inhibitory activity induced by Ac9–25 on neutrophil superoxide release could rely on several different mechanisms; there may be a direct or indirect effect of Ac9–25 on the superoxide-generating electron-transporting system; the Ac9–25 peptide may compete with the activating agonist for binding to the specific surface receptor; or binding of Ac9–25 may switch the function of the receptor toward generation of a not-yet identified inhibitory signal [37 ]. The Ac9–25 peptide was without effect on the neutrophil NADPH-oxidase activity when the cells were triggered with PMA, a neutrophil activator that bypasses all cell-surface receptors and directly activates PKC. We can thus exclude the possibility that the peptide has a direct effect on the NADPH oxidase. The fact that the inhibitory signal affects the response, not only to fMLF but to all the G protein-coupled receptor-binding agonists tested also excludes the possibility that the Ac9–25 peptide competes with the activating agonists for binding to their respective receptor. The mechanism for inactivation is not known but might involve a general down-regulation of receptor signaling or a hierarchical cross-desensitization of receptor/signaling pathways.

Ligand occupation of FPR is associated with a rapid phosphorylation and/or cytoskeleton coupling of the occupied receptor, and this results in a physical separation of the receptor from the G protein and by that, a termination of the signaling capacity. This desensitization process makes the cells unable to generate a burst of superoxide if they are challenged with a new ligand that uses the same receptor or a hierarchically subordinated receptor (e.g., CXC chemokine receptor triggered by IL-8) [38 ]. This could be the mechanism by which Ac9–25 inhibits the response to the other chemoattractants, but the inhibitory signal could probably not be generated by FPR or FPRL1, as neither of these receptors is hierarchically superior to the other or to C5aR [38 , 39 ]. The suggestion that none of the FPR family members are involved gains further support from the results obtained with receptor-specific antagonists. The inhibitory signal generated by Ac9–25 was not reversed by cyclosporin H/boc-MLF or WRWWWW, antagonists for FPR and FPRL1, respectively. Moreover, HL-60 cells allowed to differentiate in the presence of fMLF and WKYMVm display a functional NADPH-oxidase but become "nonresponders" to all agonists (including Ac9–25) operating through FPR or FPRL1. Also in these cells, Ac9–25 exercises an inhibitory effect illustrated by the fact that the response to C5a is reduced in cells challenged with the annexin AI peptide. These data strongly suggest that the inhibitory signal induced by Ac9–25 is transduced through a receptor distinct from the members of the FPR family.

We thus suggest that the inhibitory signal induced by Ac9–25 is generated by a receptor distinct from FPR and FPRL1, and this not-yet identified receptor shares some functional similarities to the neutrophil histamine receptor and the LXA4receptor. Earlier studies have revealed that histamine inhibits the NADPH oxidase-dependent formation of superoxide in a way similar to Ac9–25 [40 ]. The receptor that transduces this inhibitory signal is the H2-type histamine receptor, but the precise signal transduction mechanism triggered by this receptor has not been defined. The fact that ranitidine, an antagonist specific for the H2receptor has no effect on the Ac9–25-induced inhibition of superoxide production (data not shown) suggests that this peptide and histamine work through different receptors. Also, LXA4 has been shown to inhibit neutrophil function through FPRL1 [20 ]. We have not been able to confirm these results, but we have shown that LXA4 triggers HL-60 cells expressing FPRL1 as well as those lacking this receptor [41 ], and our earlier data thus suggest that LXA4 has a receptor that is distinct from FPRL1.

In summary, some important features of the annexin AI-derived peptide Ac9–25 and its receptors are that the peptide activates the neutrophil NADPH oxidase through FPR but not through FPRL1, the peptide inhibits the neutrophil release of superoxide anions when triggered by other chemoattractants, and the peptide most likely inhibits cell function through a receptor distinct from FPR and FPRL1.


   ACKNOWLEDGEMENTS
 
This work was supported by the Swedish Society against Cancer, Fredrik and Ingrid Thuring Foundation, the Rheumatological Society of Göteborg, the King Gustaf V 80-Year Foundation, the Vårdal Foundation, and the Swedish Medical Research Council.

Received March 16, 2005; revised April 25, 2005; accepted May 2, 2005.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Betten, A., Dahlgren, C., Mellqvist, U. H., Hermodsson, S., Hellstrand, K. (2004) Oxygen radical-induced natural killer cell dysfunction: role of myeloperoxidase and regulation by serotonin J. Leukoc. Biol. 75,1111-1115[Abstract/Free Full Text]
  2. Mellqvist, U. H., Hansson, M., Brune, M., Dahlgren, C., Hermodsson, S., Hellstrand, K. (2000) Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine Blood 96,1961-1968[Abstract/Free Full Text]
  3. Lundqvist-Gustafsson, H., Bengtsson, T. (1999) Activation of the granule pool of the NADPH oxidase accelerates apoptosis in human neutrophils J. Leukoc. Biol. 65,196-204[Abstract]
  4. Thoren, F., Romero, A., Lindh, M., Dahlgren, C., Hellstrand, K. (2004) A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of NADPH oxidase-derived oxygen radicals J. Leukoc. Biol. 76,1180-1186[Abstract/Free Full Text]
  5. Perretti, M., Gavins, F. N. (2003) Annexin 1: an endogenous anti-inflammatory protein News Physiol. Sci. 18,60-64[Abstract/Free Full Text]
  6. Getting, S. J., Flower, R. J., Perretti, M. (1997) Inhibition of neutrophil and monocyte recruitment by endogenous and exogenous lipocortin 1 Br. J. Pharmacol. 120,1075-1082[CrossRef][Medline]
  7. Harris, J. G., Flower, R. J., Perretti, M. (1995) Alteration of neutrophil trafficking by a lipocortin 1 N-terminus peptide Eur. J. Pharmacol. 279,149-157[CrossRef][Medline]
  8. Walther, A., Riehemann, K., Gerke, V. (2000) A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR Mol. Cell 5,831-840[CrossRef][Medline]
  9. Allcock, G. H., Allegra, M., Flower, R. J., Perretti, M. (2001) Neutrophil accumulation induced by bacterial lipopolysaccharide: effects of dexamethasone and annexin 1 Clin. Exp. Immunol. 123,62-67[CrossRef][Medline]
  10. Gerke, V., Moss, S. E. (2002) Annexins: from structure to function Physiol. Rev. 82,331-371[Abstract/Free Full Text]
  11. Movitz, C., Dahlgren, C. (2000) Endogenous cleavage of annexin I generates a truncated protein with a reduced calcium requirement for binding to neutrophil secretory vesicles and plasma membrane Biochim. Biophys. Acta 1468,231-238[Medline]
  12. Ernst, S., Lange, C., Wilbers, A., Goebeler, V., Gerke, V., Rescher, U. (2004) An annexin 1 N-terminal peptide activates leukocytes by triggering different members of the formyl peptide receptor family J. Immunol. 172,7669-7676[Abstract/Free Full Text]
  13. Murphy, P. M., Ozcelik, T., Kenney, R. T., Tiffany, H. L., McDermott, D., Francke, U. (1992) A structural homologue of the N-formyl peptide receptor Characterization and chromosome mapping of a peptide chemoattractant receptor family. J. Biol. Chem. 267,7637-7643
  14. Fiore, S., Maddox, J. F., Perez, H. D., Serhan, C. N. (1994) Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor J. Exp. Med. 180,253-260[Abstract/Free Full Text]
  15. Bylund, J., Christophe, T., Boulay, F., Nystrom, T., Karlsson, A., Dahlgren, C. (2001) Proinflammatory activity of a cecropin-like antibacterial peptide from Helicobacter pylori Antimicrob. Agents Chemother. 45,1700-1704[Abstract/Free Full Text]
  16. Christophe, T., Karlsson, A., Dugave, C., Rabiet, M. J., Boulay, F., Dahlgren, C. (2001) The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2 J. Biol. Chem. 276,21585-21593[Abstract/Free Full Text]
  17. Su, S. B., Gong, W., Gao, J. L., Shen, W., Murphy, P. M., Oppenheim, J. J., Wang, J. M. (1999) A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells J. Exp. Med. 189,395-402[Abstract/Free Full Text]
  18. Dahlgren, C., Christophe, T., Boulay, F., Madianos, P. N., Rabiet, M. J., Karlsson, A. (2000) The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor Blood 95,1810-1818[Abstract/Free Full Text]
  19. Gewirtz, A. T., Fokin, V. V., Petasis, N. A., Serhan, C. N., Madara, J. L. (1999) LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulation Am. J. Physiol. 276,C988-C994
  20. Takano, T., Fiore, S., Maddox, J. F., Brady, H. R., Petasis, N. A., Serhan, C. N. (1997) Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors J. Exp. Med. 185,1693-1704[Abstract/Free Full Text]
  21. Perretti, M., Getting, S. J., Solito, E., Murphy, P. M., Gao, J. L. (2001) Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics Am. J. Pathol. 158,1969-1973[Abstract/Free Full Text]
  22. Gavins, F. N., Kamal, A. M., D’Amico, M., Oliani, S. M., Perretti, M. (2005) Formyl-peptide receptor is not involved in the protection afforded by annexin 1 in murine acute myocardial infarct FASEB J. 19,100-102[Abstract/Free Full Text]
  23. Bae, Y. S., Lee, H. Y., Jo, E. J., Kim, J. I., Kang, H. K., Ye, R. D., Kwak, J. Y., Ryu, S. H. (2004) Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling J. Immunol. 173,607-614[Abstract/Free Full Text]
  24. Fu, H., Bjorkman, L., Janmey, P., Karlsson, A., Karlsson, J., Movitz, C., Dahlgren, C. (2004) The two neutrophil members of the formylpeptide receptor family activate the NADPH-oxidase through signals that differ in sensitivity to a gelsolin-derived phosphoinositide-binding peptide BMC Cell Biol. 5,50[CrossRef][Medline]
  25. Boyum, A. (1968) Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J. Clin. Lab. Invest. Suppl. 97,77-89
  26. Lundqvist, H., Dahlgren, C. (1996) Isoluminol-enhanced chemiluminescence: a sensitive method to study the release of superoxide anion from human neutrophils Free Radic. Biol. Med. 20,785-792[CrossRef][Medline]
  27. Almkvist, J., Dahlgren, C., Leffler, H., Karlsson, A. (2002) Activation of the neutrophil nicotinamide adenine dinucleotide phosphate oxidase by galectin-1 J. Immunol. 168,4034-4041[Abstract/Free Full Text]
  28. Dahlgren, C., Karlsson, A. (1999) Respiratory burst in human neutrophils J. Immunol. Methods 232,3-14[CrossRef][Medline]
  29. Karlsson, A., Dahlgren, C. (2002) Assembly and activation of the neutrophil NADPH oxidase in granule membranes Antioxid. Redox Signal. 4,49-60[CrossRef][Medline]
  30. Bylund, J., Pellme, S., Fu, H., Mellqvist, U. H., Hellstrand, K., Karlsson, A., Dahlgren, C. (2004) Cytochalasin B triggers a novel pertussis toxin-sensitive pathway in TNF-{alpha} primed neutrophils BMC Cell Biol. 5,21[CrossRef][Medline]
  31. Bylund, J., Karlsson, A., Boulay, F., Dahlgren, C. (2002) Lipopolysaccharide-induced granule mobilization and priming of the neutrophil response to Helicobacter pylori peptide Hp(2–20), which activates formyl peptide receptor-like 1 Infect. Immun. 70,2908-2914[Abstract/Free Full Text]
  32. Le, Y., Gong, W., Tiffany, H. L., Tumanov, A., Nedospasov, S., Shen, W., Dunlop, N. M., Gao, J. L., Murphy, P. M., Oppenheim, J. J., Wang, J. M. (2001) Amyloid (ß)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1 J. Neurosci. 21,RC123
  33. Seifert, R., Wenzel-Seifert, K. (2003) The human formyl peptide receptor as model system for constitutively active G-protein-coupled receptors Life Sci 73,2263-2280[CrossRef][Medline]
  34. Le, Y., Ye, R. D., Gong, W., Li, J., Iribarren, P., Wang, J. M. (2005) Identification of functional domains in the formyl peptide receptor-like 1 for agonist-induced cell chemotaxis FEBS J. 272,769-778
  35. De Yang, Chen, . Q.,Schmidt, A. P., Anderson, G. M., Wang, J. M., Wooters, J., Oppenheim, J. J., Chertov, O. (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells J. Exp. Med. 192,1069-1074[Abstract/Free Full Text]
  36. Su, S. B., Gao, J., Gong, W., Dunlop, N. M., Murphy, P. M., Oppenheim, J. J., Wang, J. M. (1999) T21/DP107, a synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors J. Immunol. 162,5924-5930[Abstract/Free Full Text]
  37. Chiang, N., Fierro, I. M., Gronert, K., Serhan, C. N. (2000) Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation J. Exp. Med. 191,1197-1208[Abstract/Free Full Text]
  38. Fu, H., Bylund, J., Karlsson, A., Pellme, S., Dahlgren, C. (2004) The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8 Immunology 112,201-210[CrossRef][Medline]
  39. Heit, B., Tavener, S., Raharjo, E., Kubes, P. (2002) An intracellular signaling hierarchy determines direction of migration in opposing chemotactic gradients J. Cell Biol. 159,91-102[Abstract/Free Full Text]
  40. Betten, A., Dahlgren, C., Hermodsson, S., Hellstrand, K. (2003) Histamine inhibits neutrophil NADPH oxidase activity triggered by the lipoxin A4 receptor-specific peptide agonist Trp-Lys-Tyr-Met-Val-Met Scand. J. Immunol. 58,321-326[CrossRef][Medline]
  41. Christophe, T., Karlsson, A., Rabiet, M. J., Boulay, F., Dahlgren, C. (2002) Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4 Scand. J. Immunol. 56,470-476[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
L. Bjorkman, J. Karlsson, A. Karlsson, M.-J. Rabiet, F. Boulay, H. Fu, J. Bylund, and C. Dahlgren
Serum amyloid A mediates human neutrophil production of reactive oxygen species through a receptor independent of formyl peptide receptor like-1
J. Leukoc. Biol., February 1, 2008; 83(2): 245 - 253.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Bellner, J. Karlsson, H. Fu, F. Boulay, C. Dahlgren, K. Eriksson, and A. Karlsson
A Monocyte-Specific Peptide from Herpes Simplex Virus Type 2 Glycoprotein G Activates the NADPH-Oxidase but Not Chemotaxis through a G-Protein-Coupled Receptor Distinct from the Members of the Formyl Peptide Receptor Family
J. Immunol., November 1, 2007; 179(9): 6080 - 6087.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. P. G. Hayhoe, A. M. Kamal, E. Solito, R. J. Flower, D. Cooper, and M. Perretti
Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement
Blood, March 1, 2006; 107(5): 2123 - 2130.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
H. Fu, J. Karlsson, J. Bylund, C. Movitz, A. Karlsson, and C. Dahlgren
Ligand recognition and activation of formyl peptide receptors in neutrophils
J. Leukoc. Biol., February 1, 2006; 79(2): 247 - 256.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0305153v1
78/3/762    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karlsson, J.
Right arrow Articles by Movitz, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karlsson, J.
Right arrow Articles by Movitz, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS